Tag: non-Hodgkin’s lymphoma
GTB-1550 Shows Durable Complete Remission in Patients with Chemotherapy-refractory B-cell Malignancies
The investigational anti-cancer agent GTB-1550, also known as OXS-1550 or DT2219 is a novel multi-target directed therapy for the treatment of chemotherapy-refractory B-cell malignancies,...
Sutro Partners with The Leukemia & Lymphoma Society to Develop STRO-001
Earlier today Sutro Biopharma, a clinical-stage drug discovery, development and manufacturing company, and The Leukemia & Lymphoma Society®, the world's largest voluntary health agency...
Interim Data Shows Favorable Tolerability and Efficacy Results of ADCT-301 in...
Interim results from an ongoing Phase I, open label, dose-escalating study evaluating ADCT-301, being developed by ADC Therapeutics for the treatment of relapsed or refractory...
Phase I Study Supports Therapeutic Potential of Polatuzumab Vedotin in non-Hodgkin...
Lymphoma - with its main forms Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) - is the most common blood cancer which occurs when cells...
Harnessing the Power of Three: Advancing Antibody-Drug Conjugates from Laboratory to...
Antibody-drug conjugates or ADCs are creating much excitement among life science professionals, medical/clinical research scientists and pharmaceutical specialists. At the same time, oncologists and hematologists are eager to welcome new treatment options in the ongoing war against cancer. This article reviews some of the advances made in the development of ADCs.
